Evidence map›Paper›PMID 40176833›Full record

ArticleMolecular syndromology2025

Clinical and Radiological Profile of Nine Patients with Metachromatic Leukodystrophy.

Çiğdem Seher Kasapkara, Burcu Civelek Ürey, Berrak Bilginer Gürbüz, Aynur Küçükçongar Yavaş, Avni Merter Keçeli, Ümmühan Öncül, Mehmet Gündüz, Gürsel Biberoğlu, Ayşegül Neşe Çıtak Kurt, Esra Gürkaş and 3 more

Erratum issuedAbstract read
In one paragraph

Article in Molecular syndromology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Çiğdem Seher KasapkaraDepartment of Pediatric Metabolism, Ankara Bilkent City Hospital, Ankara, Turkey.
Burcu Civelek ÜreyDepartment of Pediatric Metabolism, Ankara Bilkent City Hospital, Ankara, Turkey.
Berrak Bilginer GürbüzDepartment of Pediatric Metabolism, Ankara Bilkent City Hospital, Ankara, Turkey.
Aynur Küçükçongar YavaşDepartment of Pediatric Metabolism, Ankara Bilkent City Hospital, Ankara, Turkey.
Avni Merter KeçeliDepartment of Pediatric Radiology, Ankara Bilkent City Hospital, Ankara, Turkey.
Ümmühan ÖncülDepartment of Pediatric Metabolism, Ankara Bilkent City Hospital, Ankara, Turkey.
Mehmet GündüzDepartment of Pediatric Metabolism, Ankara Bilkent City Hospital, Ankara, Turkey.
Gürsel BiberoğluDepartment of Pediatric Metabolism, Gazi University Hospital, Ankara, Turkey.
Ayşegül Neşe Çıtak KurtDepartment of Pediatric Neurology, Ankara Bilkent City Hospital, Ankara, Turkey.
Esra GürkaşDepartment of Pediatric Neurology, Ankara Bilkent City Hospital, Ankara, Turkey.
Esra KılıçDepartment of Pediatric Genetics, Ankara Bilkent City Hospital, Ankara, Turkey.
Gülay Güleç CeylanDepartment of Medical Genetics, Ankara Bilkent City Hospital, Ankara, Turkey.
Namık Yaşar ÖzbekDepartment of Pediatric Hematology, Ankara Bilkent City Hospital, Ankara, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Metachromatic leukodystrophy (MLD) is a rare, demyelinating, autosomal recessive lysosomal storage disease caused by a deficiency in the arylsulfatase A enzyme (ASA), which is encoded by Methods: We present a total of 9 patients with MLD with an average age of 61 months, whose clinical, laboratory and cranial magnetic resonance imaging findings were evaluated, and who underwent an Results: Of the 9 patients, 7 had the late infantile form of the condition, 2 had the juvenile form, and 3 were identified through family screening. The median age at diagnosis was 30 months (min 3-max 73 months), the mean ASA activity value was 2 nmol/h/mgprt and the median cranial MR imaging severity score was 10 (min 5-max 18). The grey and white matter volumes of all patients, evaluated using volBrain software, were within the normal range. At an average age of 48 months, the late-infantile MLD patients were unable to control any body part. Conclusions: Hematopoietic stem cell transplantation (HSCT), a treatment option for both the juvenile and adult forms of MLD in asymptomatic or early symptomatic patients, was performed on two of the asymptomatic and early symptomatic patients, and post-HSCT ASA activity settled within the normal range and their developmental milestones stabilized. It is important to diagnose MLD in the asymptomatic period and newborn screening can support early diagnosis.

Indexed as

ARSA geneArylsulfatase A enzymeMetachromatic leukodystrophy

Identifiers

PMID40176833
PMCPMC11961098

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.